In view of the array of symptoms, the patient was referred for medical evaluation of a suspected pheochromocytoma, a neuroendocrine tumor of the adrenal gland. He underwent 24-hour blood pressure ...
The First International Symposium on Pheochromocytoma, held in October 2005, included discussions about developments concerning these rare catecholamine-producing tumors. Recommendations were made ...
Patients with optic disc edema are often brought to the attention of ophthalmologists either as referrals from internists or as a first consultation by a patient with visual symptoms. The ...
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
A pheochromocytoma is a tumor that produces adrenaline ... Usually, it presents with no apparent signs or symptoms, unless the adrenal glands are producing excessive hormones (such as cortisol and ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...
Pheochromocytomas and paragangliomas are rare tumors, but their investigation and management are complex and expensive, both in terms of time and resources. A novel prospective study ...
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback